Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
Results of this large, real-world study demonstrated that all treatment groups experienced an increase in the rates of AEs over time, including ADT alone. Most AE rates with ADT + ARPIs were comparable with ADT + NSAA and not significantly different from ADT alone. ADT + docetaxel cohort was associated with significantly higher rates for all AEs over time except hypertension, sexual dysfunction, and pain. This study provides real-world evidence on AEs, beyond controlled clinical trials, and may assist healthcare providers to make better-informed decisions about disease management among patients with mCSPC.
Authors
- Hongbo Yang (ORCID: https://orcid.org/0000-0003-2741-8418)
- Christopher J. Young (ORCID: https://orcid.org/0000-0002-7213-5137)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Lisa Mucha
- Nader N. El-Chaar
- Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
- Bin Xie
- Yao Wang (ORCID: https://orcid.org/0000-0001-6672-9601)
- Wei Gao (ORCID: https://orcid.org/0000-0002-4088-3210)
Institutions
- Pfizer (United States) (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Astellas Pharma (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- The Prostate
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1002/pros.24777
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Pfizer
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders